肠促胰素类多肽对非酒精性脂肪性肝病的影响  

Effect of Incretogenic Peptides on Non-Alcoholic Fatty Liver Disease

作　　者：苏怡平 马晓梅[2] 

机构地区：[1]青海大学研究生院,青海 西宁 [2]青海大学附属医院内分泌与代谢病科,青海 西宁

出　　处：《临床医学进展》2023年第6期9987-9995,共9页Advances in Clinical Medicine

摘　　要：目前,非酒精性脂肪性肝病(NAFLD)是最常见的肝病,影响高达70%的糖尿病患者,尚无特效药可用于治疗。GLP-1受体激动剂(GLP-1 RA)除了其抗高血糖作用和令人惊讶的心肾保护作用外,对NAFLD患者的体重以及脂肪肝和纤维化的临床、生化和组织学标志物具有显著影响。因此,GLP-1 RAs可能是治疗糖尿病和NAFLD的武器。本综述的目的是总结目前可获得的关于GLP-1 RAs在NAFLD治疗中作用的证据,并假设未来的潜在情况。At present, non-alcoholic fatty liver disease (NAFLD) is the most common liver disease, affecting up to 70% of diabetic patients, and there is no specific drug for treatment. GLP-1 receptor agonists (GLP-1 RA) have significant effects on body weight and clinical, biochemical, and histological mark-ers of fatty liver and fibrosis in patients with NAFLD, in addition to their anti-hyperglycemic effect and surprising cardio-renal protection. Therefore, GLP-1 RAs may be a weapon in the treatment of diabetes and NAFLD. The purpose of this review was to summarize the currently available evidence on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios.

关 键 词：非酒精性脂肪性肝病 2型糖尿病 胰高血糖素样肽-1 胰高血糖素样肽-1受体激动剂 

分 类 号：R57[医药卫生—消化系统]